Sanofi (SNW2) - Total Liabilities
Based on the latest financial reports, Sanofi (SNW2) has total liabilities worth €56.26 Billion EUR (≈ $65.78 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sanofi - Total Liabilities Trend (2016–2024)
This chart illustrates how Sanofi's total liabilities have evolved over time, based on quarterly financial data. See SNW2 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Sanofi Competitors by Total Liabilities
The table below lists competitors of Sanofi ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BP p.l.c
MX:BPN
|
Mexico | MX$224.78 Billion |
|
Lockheed Martin Corporation
NYSE:LMT
|
USA | $54.09 Billion |
|
Quanta Services Inc
NYSE:PWR
|
USA | $16.60 Billion |
|
Mizuho Financial Group Inc.
NYSE:MFG
|
USA | $286.31 Trillion |
|
Medtronic plc
SA:MDTC34
|
Brazil | R$42.50 Billion |
|
Marriott International Inc
NASDAQ:MAR
|
USA | $31.95 Billion |
|
Canadian Imperial Bank Of Commerce
TO:CM
|
Canada | CA$1.09 Trillion |
|
Sanofi
MX:SNYN
|
Mexico | MX$54.88 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Sanofi's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sanofi (SNW2) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sanofi's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sanofi (2016–2024)
The table below shows the annual total liabilities of Sanofi from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €54.94 Billion ≈ $64.23 Billion |
+5.43% |
| 2023-12-31 | €52.11 Billion ≈ $60.92 Billion |
+2.03% |
| 2022-12-31 | €51.07 Billion ≈ $59.71 Billion |
-0.27% |
| 2021-12-31 | €51.21 Billion ≈ $59.87 Billion |
-0.33% |
| 2020-12-31 | €51.38 Billion ≈ $60.07 Billion |
-4.19% |
| 2019-12-31 | €53.63 Billion ≈ $62.70 Billion |
+2.40% |
| 2018-12-31 | €52.37 Billion ≈ $61.23 Billion |
+25.99% |
| 2017-12-31 | €41.57 Billion ≈ $48.60 Billion |
-11.46% |
| 2016-12-31 | €46.95 Billion ≈ $54.89 Billion |
-- |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting aga… Read more